CMPX (Compass Therapeutics) OCF Margin %: 0.00% (As of Mar. 2026)


CMPX Compass Therapeutics Inc CMPX
23 GF Score
Price $2.34
! 2 Warning Signs
View Full Analysis

What is Compass Therapeutics OCF Margin %?

Compass Therapeutics CMPX +0.86% 23 OCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates CMPX with a GF Score™ of 23/100. The stock has 2 warning signs investors should review. Among 948 Biotechnology companies, Compass Therapeutics ranks worse than 105485.13% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Compass Therapeutics's Cash Flow from Operations for the three months ended in Mar. 2026 was $-17.27 Mil. Compass Therapeutics's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Compass Therapeutics's OCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Compass Therapeutics's current OCF Yield % is -12.63%.

The historical rank and industry rank for Compass Therapeutics's OCF Margin % or its related term are showing as below:


During the past 8 years, the highest OCF Margin % of Compass Therapeutics was -5277.06%. The lowest was -5277.06%. And the median was -5277.06%.

CMPX's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -64.115
* Ranked among companies with meaningful OCF Margin % only.

Compass Therapeutics OCF Margin % Related Terms

Compass Therapeutics OCF Margin % Historical Data

* Premium members only.

The historical data trend for Compass Therapeutics's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Compass Therapeutics OCF Margin % Chart

Compass Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 -5,277.06 0.00

Compass Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CMPX
23GF Score
Compass Therapeutics Inc CMPX
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Compass Therapeutics OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Compass Therapeutics's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-49.143/0
= %

Compass Therapeutics's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-17.269/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Compass Therapeutics (CMPX) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Compass Therapeutics and its competitors. According to the industry distribution chart, Compass Therapeutics ranks #999999 out of 948 companies in the Biotechnology industry.
Is Compass Therapeutics' OCF Margin % too high?
Compass Therapeutics' current OCF Margin % is 0.00%. Based on the distribution chart, Compass Therapeutics ranks #999999 out of 948 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Compass Therapeutics has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Compass Therapeutics' OCF Margin % compare to XFOR and LRMR?
According to the Biotechnology industry distribution chart, Compass Therapeutics ranks #999999 out of 948 companies for OCF Margin %. This places Compass Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Compass Therapeutics and its competitors. Compass Therapeutics's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Compass Therapeutics stock overvalued right now?
Compass Therapeutics (CMPX) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Compass Therapeutics' overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Compass Therapeutics (CMPX), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Compass Therapeutics Business Description

Address 80 Guest Street, Suite 601, Boston, MA, USA, 02135
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.
23GF Score

Get the complete analysis for CMPX

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.34
Price